Best Peptide Protocols
    ResearchJan 28, 202613 min

    Tesamorelin vs Ipamorelin vs CJC-1295: Choosing a GH Secretagogue Protocol

    Three different growth hormone secretagogues, three different mechanisms, three different use cases. A complete comparison of the most studied GH-optimizing peptides and how to select and stack them.

    Why GH Secretagogues Instead of Growth Hormone?

    Growth hormone secretagogues (GHSs) stimulate the pituitary to produce its own GH rather than directly supplementing GH. This has several research advantages:

  1. Preservation of pulsatility: Natural GH is released in pulses — especially during sleep. Exogenous GH flattens this rhythm. GH secretagogues can preserve or enhance natural pulsatile patterns.
  2. Feedback regulation: The hypothalamic-pituitary axis maintains feedback control even with secretagogue use, preventing GH levels from rising to supraphysiological levels.
  3. Somatostatin interaction: The natural somatostatin system (which suppresses GH) continues to function, providing a built-in brake.

    4. The three most studied injectable GH secretagogues — tesamorelin, ipamorelin, and CJC-1295 — work through different receptors and produce distinct profiles.

    The Three Receptors Behind GH Release

    Understanding secretagogue differences requires knowing the two primary GH-stimulating pathways:

    GHRH pathway (Growth Hormone-Releasing Hormone)

  4. Stimulates GHRH receptors on pituitary somatotrophs
  5. Produces sustained, physiologic GH release patterns
  6. Not directly affected by fed/fasted state (relatively meal-independent)
  7. Tesamorelin and CJC-1295 work through this pathway

    8. Ghrelin pathway (GHS-R1a receptor)

  8. Stimulates the ghrelin receptor on pituitary and hypothalamic cells
  9. Produces pulsatile, robust GH release
  10. Can be amplified by fasted states
  11. Ipamorelin works through this pathway

    12. GHRH + Ghrelin together: When both pathways are stimulated simultaneously (via a stack of GHRH analog + ghrelin mimetic), the effect is synergistic — GH pulses 5–10× above either compound alone.

    Tesamorelin: The FDA-Approved GHRH Analog

    Mechanism

    Tesamorelin is a 44-amino acid synthetic analog of the full human GHRH sequence — the entire natural GHRH molecule with a trans-3-hexenoic acid modification that stabilizes the N-terminus against rapid enzymatic degradation. This gives tesamorelin a longer effective half-life than native GHRH.

    Why It Stands Out

    Tesamorelin is the only FDA-approved GHRH analog — approved as Egrifta® for treating visceral fat accumulation (lipodystrophy) in HIV-infected patients. This approval reflects the highest tier of clinical evidence among all GH secretagogues: Phase III randomized controlled trials demonstrating safety and efficacy in humans.

    The FDA-approval context provides important data for researchers:

  12. Established human dosing: 2 mg/day subcutaneous
  13. Documented effects: Significant visceral fat reduction, improved trunk-to-limb fat ratio, elevated IGF-1 without glucose impairment
  14. Safety profile: Well-characterized across multiple studies

    15. Cognitive Research

    Beyond metabolic effects, tesamorelin has been studied for cognitive benefits in older adults:

  15. Improved verbal memory and executive function in adults with mild cognitive impairment
  16. Preserved hippocampal volume in longitudinal studies
  17. These CNS effects appear to be IGF-1 mediated rather than direct GH effects

    18. Research Protocol

  18. Vial: 5 mg or 10 mg lyophilized
  19. Reconstitution: 2.5 mL BAC water → 2 mg/mL (5 mg vial)
  20. Dose: 1–2 mg once daily, subcutaneous
  21. Timing: Evening or before bed to align with natural GH pulse
  22. Cycle: 12–16 weeks on, 4–8 weeks off

    23. Best For

  23. Visceral fat reduction protocols
  24. Cognitive enhancement alongside metabolic benefit
  25. Protocols requiring the most robust human clinical evidence
  26. Researchers who want alignment with an approved drug's studied dosing

    27. Ipamorelin: The Selective Ghrelin Mimetic

    Mechanism

    Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHS-R1a) with high selectivity. Among all GHRPs, ipamorelin has the cleanest selectivity profile — it stimulates GH release with minimal effect on cortisol, prolactin, ACTH, or appetite.

    This selectivity is ipamorelin's defining characteristic: it produces the GH pulse without the side effects commonly associated with other GHRPs.

    Comparing GHRPs: Why Ipamorelin Is Often Preferred

    GHRPGH ReleaseCortisolProlactinAppetiteDesensitization Rate
    GHRP-2++++++++Moderate
    GHRP-6+++++++Moderate
    Hexarelin+++++++++++High
    Ipamorelin++MinimalMinimalMinimalLow

    Ipamorelin sacrifices some raw GH release potency compared to GHRP-2 or Hexarelin, but trades this for dramatically improved tolerability and lower desensitization rate — making it more suitable for sustained research protocols.

    Research Protocol

  27. Vial: 5 mg or 10 mg lyophilized
  28. Reconstitution: 2.5 mL BAC water → 2 mg/mL (5 mg vial)
  29. Dose: 100–300 mcg per dose, 2–3× daily
  30. Timing: Fasted morning, pre-workout, and/or before bed
  31. Cycle: 8–12 weeks on, 4–6 weeks off

    32. Best For

  32. Protocols requiring clean GH stimulation without cortisol/prolactin elevation
  33. Daily multi-dose protocols
  34. Stacking with GHRH analogs for synergistic GH release
  35. Researchers sensitive to GHRP side effects

    36. CJC-1295: Long-Acting vs. Short-Acting GHRH

    CJC-1295 exists in two distinct formulations with very different pharmacokinetic profiles:

    CJC-1295 No DAC (Modified GRF 1-29)

    Mechanism: A 29-amino acid GHRH fragment with four amino acid substitutions for stability. Without the Drug Affinity Complex, it has a half-life of ~30 minutes — producing a pulsatile GH response that closely mimics natural GHRH release patterns.

    Research Protocol:

  36. Vial: 5 mg lyophilized
  37. Reconstitution: 2.5 mL BAC water → 2 mg/mL
  38. Dose: 100–300 mcg per dose, 2–3× daily (typically paired with Ipamorelin)
  39. Timing: Fasted morning and/or before bed
  40. Cycle: 12–16 weeks on, 4–8 weeks off

    41. Best For: Precise pulsatile GH stimulation, stacking with Ipamorelin for synergistic effect, protocols mimicking natural GHRH patterns.

    CJC-1295 DAC

    Mechanism: The same GHRH fragment but with a Drug Affinity Complex (maleimidopropionic acid) that binds to serum albumin in blood, extending the half-life to 6–8 days. A single injection maintains GH elevation for up to 6 days.

    Research Protocol:

  41. Vial: 5 mg lyophilized
  42. Reconstitution: 2 mL BAC water → 2.5 mg/mL
  43. Dose: 1–2 mg once weekly or bi-weekly
  44. Timing: Day of the week consistent
  45. Cycle: 8–10 weeks on, 4–6 weeks off

    46. Best For: Less frequent dosing schedule, sustained (rather than pulsatile) GH elevation, protocols where daily injection is impractical.

    Important consideration: The persistent GHRH receptor stimulation from DAC may produce different downstream biology than pulsatile stimulation. Natural GH release is pulsatile, not tonic; continuous GHRH receptor activation does not mimic natural physiology as closely as no-DAC protocols.

    The Classic Stack: Ipamorelin + CJC-1295 No DAC

    This combination is the most studied GH secretagogue stack in research literature and the most prescribed in clinical longevity medicine. The rationale is dual-pathway synergy:

  46. CJC-1295 No DAC stimulates via GHRH receptor
  47. Ipamorelin stimulates via ghrelin receptor
  48. Together: 5–10× greater GH pulse than either alone

    49. Standard research protocol:

  49. CJC-1295 No DAC 200 mcg + Ipamorelin 200–300 mcg
  50. Administered together once daily (typically before bed or fasted morning)
  51. 8–12 weeks on, 4 weeks off

    52. This combination is available as a pre-formulated 5mg/5mg blend on the site, simplifying the dosing process.

    Selecting a Protocol: Decision Framework

    Choose Tesamorelin when:

  52. Visceral fat reduction is the primary research objective
  53. You want the compound with the strongest human clinical data
  54. Cognitive + metabolic dual benefit is desired
  55. FDA-approved dosing precedent matters for protocol design

    56. Choose Ipamorelin when:

  56. Clean GH pulse without cortisol/prolactin elevation is required
  57. Daily multi-dose protocol is feasible
  58. GHS-R1a pathway research is the objective
  59. You intend to stack with a GHRH analog

    60. Choose CJC-1295 No DAC when:

  60. Pulsatile, physiological GHRH pattern is desired
  61. Daily injection is feasible
  62. Stacking with Ipamorelin for synergy

    63. Choose CJC-1295 DAC when:

  63. Weekly dosing schedule is preferred over daily
  64. Sustained (not pulsatile) GH elevation is the research objective
  65. Convenience outweighs physiological precision

    66. Choose the Ipamorelin + CJC-1295 No DAC stack when:

  66. Maximum GH pulse amplitude within physiological range is the objective
  67. Simplicity and most-studied combination is preferred
  68. Both once-daily and split dosing are feasible

    69. Important Note

    This article is for educational and research reference purposes only. None of the compounds described here — except tesamorelin (Egrifta®) for its specific approved indication — are FDA-approved for general use. All protocols described reflect the research literature. Consult a licensed healthcare provider for any clinical application.